Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 4, 2024Blood Cancer Discovery

Abstract P39: CFT7455, a novel IKZF1/3 degrader enhances the anti-myeloma activity of monoclonal and bispecific antibodies by augmenting immune responses

View Full Paper
Ask AI
Bookmark
Share

Authors

JTJennifer TotmanC4 Therapeutics (United States)VBVanessa C. Bret-MounetBeth Israel Deaconess Medical CenterSPSamantha PerinoNGM Biopharmaceuticals (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Totman et al. (2024) studied this question.

synapsesocial.com/papers/68e75c84b6db6435876d3359https://doi.org/10.1158/2643-3249.bcdsymp24-p39
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 1237: IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma2024 · 1 citations
  2. 2Abstract 3510: High-dose FcRH5xCD3 T-cell-engaging bispecific antibody (TCB) overcomes Treg-mediated suppression in-vitro in multiple myeloma2026
  3. 3Abstract 2405: A first-in-class IKZF1/3 degrader antibody conjugate (DAC) as a potential myeloma treatment.2026
  4. 4Abstract 2656: The selective IKZF2 molecular glue degrader, PVTX-405, counters Treg immune suppression,shows significant tumor growth delay as single agent and synergistic response with immune checkpoint therapies (ICTs)2024 · 1 citations
  5. 5Abstract 1238: ISB 2001, a BCMA and CD38 dual targeting T cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patient relapsing from CD38 and BCMA targeted immunotherapies2024